Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CRHBP | P24387 | 2/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23735384 | 0.80 | CD44 (0.47) | ITGB2ICAM1ITGALADRB1KEAP1 | |
| SCHEMBL19711047 | 0.80 | ITGB2 (0.35) | ITGB2ICAM1ITGALADRB1KEAP1 | |
| SCHEMBL19684558 | 0.80 | MAP3K14 (0.41) | ITGB2ICAM1ITGALADRB1KEAP1 | |
| SCHEMBL19667519 | 0.80 | PNMT (0.41) | ITGB2ICAM1ITGALADRB1KEAP1 | |
| SCHEMBL21800420 | 0.77 | PNMT (0.44) | ITGB2ICAM1ITGALADRB1KEAP1 | |
| SCHEMBL31634086 | 0.76 | ITGB2 (0.42) | ITGB2ICAM1ITGALAHRSMN1; SMN2 | |
| SCHEMBL964309 | 0.76 | ITGB2 (0.42) | ITGB2ICAM1ITGALAHRSMN1; SMN2 | |
| SCHEMBL19678834 | 0.76 | SSTR4 (0.36) | ITGB2ICAM1ITGALADRB1KEAP1 | |
| SCHEMBL1895331 | 0.76 | FABP6 (0.37) | FABP6 | |
| Hydrochloric Acid SCHEMBL3276367 | 0.75 | PRCP (0.54) | ITGB2ICAM1ITGALLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-110913858-B | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3782996-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-02-24 | — | — | EP | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | ITGB2 2419/4885ICAM1 3905/4885ITGAL 3044/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | ITGB2 2419/4885ICAM1 3905/4885ITGAL 3044/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | ITGB2 2419/4885ICAM1 3905/4885ITGAL 3044/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | ITGB2 2419/4885ICAM1 3905/4885ITGAL 3044/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | ITGB2 2419/4885ICAM1 3905/4885ITGAL 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.